Track Immunovant, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Immunovant, Inc. IMVT · Stock Open Immunovant, Inc. in new tab

34.18 USD
EPS
-2.56
P/B
11.24
ROE
-86.51
Beta
0.94
Target Price
48.31 USD
Immunovant, Inc. logo

Immunovant, Inc.

🧾 Earnings Recap – Q2 2027

Roivant’s shares rose 15.1% after the company reported $31 million in initial LISRAYA revenue and said its IMVT-1402 rheumatoid arthritis study met its Period 2 primary endpoint. The positive updates were tempered by management’s decision not to advance the Sjögren’s program, while it cautioned that the launch is early and September-quarter revenue benefited from pharmacy stocking.

  • LISRAYA generated $31 million in net revenue during five weeks on the market; hundreds of patients were on paid drug at quarter-end, and management said some inventory held by specialty pharmacies had been dispensed after September 30.
  • Management expects pharmacy inventory dynamics to be a modest headwind in the December quarter, but to become irrelevant next year; it said payer policies are still developing and vary in difficulty.
  • IMVT-1402 met the primary endpoint in Period 2 of its RA study, a randomized-withdrawal phase testing maintenance of ACR20 response on 600 mg, 300 mg, or placebo.
  • Roivant said it is unlikely to progress the Sjögren’s program, citing updates in the field; it plans to run the study out and learn from it.
  • Management cited roughly 85,000 U.S. patients with RA who have struggled to get adequately treated, but said it will discuss the commercial opportunity at its December Investor Day.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 5, 2027
EPS-2.56
Book Value3.18
Price to Book11.24
Debt/Equity0.01
% Insiders55.904%
Estimates
Forward P/E-13.65
Forward EPS-2.62
Target Mean Price48.31

DCF valuation

Model fair value for Immunovant, Inc. (IMVT)
Result
Sign in to run the valuation for IMVT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
16 analysts · consensus Buy · mean target 48.31 USD (low 30.00, high 62.00) · as of 11 Nov 2026
Low 30.00
Mean 48.31
High 62.00
Price 34.18
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Immunovant, Inc. Logo Immunovant, Inc. Analysis (IMVT)

United States Health Care Official Website Stock

Is Immunovant, Inc. a good investment? Immunovant, Inc. (IMVT) is currently trading at 34.18 USD. Market analysts have a consensus price target of 48.31 USD. This suggests a potential upside from current levels.

Earnings Schedule: Immunovant, Inc. is expected to release its next earnings report on Feb. 5, 2027. The market consensus estimate for Forward EPS is -2.62.

Investor FAQ

Does Immunovant, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Immunovant, Inc.?

Immunovant, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 5, 2027. The company currently has a trailing EPS of -2.56.

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Exchange Ticker
NMS (United States) IMVT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion